A recent study published in the Journal of Primary Care & Community Health describes how a man prescribed semaglutide for obesity experienced a significant decrease in alcohol consumption over a ten-month period, according to an April 2 report. The case adds to evidence suggesting that Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), originally developed for weight management, may help reduce alcohol cravings.
This topic is important as Alcohol Use Disorder (AUD) remains a widespread public health issue. Government records from the United States indicate that approximately 29 million Americans are affected by AUD out of about 133 million people who consume alcohol. Despite more than 60 million citizens reporting binge drinking, fewer than 10% of those diagnosed with AUD receive any form of treatment, and only about 2% use evidence-based pharmacotherapy.
The study focused on a 34-year-old male patient with class 2 obesity and comorbidities including bipolar disorder and generalized anxiety disorder. He was referred to a family medicine clinic for medication therapy management. His initial Alcohol Use Disorders Identification Test (AUDIT) score was high at 27, reflecting frequent heavy drinking episodes—about fifteen drinks per week and regular binge sessions.
Treatment began with semaglutide at an initial dose of 0.25 mg weekly in August 2024, increasing to a maintenance dose of 2.4 mg by May the following year. Over ten months, his BMI dropped from 37.0 to 28.6 and his alcohol intake fell dramatically—from roughly fifteen drinks per week down to half a beer per month after reaching the full dosage of semaglutide. His AUDIT score improved from high-risk levels down to seven points; projections suggested it could fall further if current patterns continued.
Clinicians reported that the patient did not experience withdrawal symptoms or desire to drink during this period and noted improvements in mood stability related to better-managed bipolar disorder symptoms. However, they emphasized this is just one case and called for larger clinical trials before considering GLP-1 RAs as primary treatments for AUD.
The authors also highlighted that stigma prevented the patient from initially disclosing his drinking habits, pointing out the need for stronger screening efforts within primary care settings.
